Cassava Sciences (Cassava Sciences) Cash Flow from Operations

: $-82.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Cassava Sciences's Net Income From Continuing Operations was $-20.92 Mil. Its Depreciation, Depletion and Amortization was $0.36 Mil. Its Change In Working Capital was $-3.88 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $2.13 Mil. And its Cash Flow from Others was $-0.00 Mil. In all, Cassava Sciences's Cash Flow from Operations for the three months ended in Dec. 2023 was $-22.32 Mil.

Cassava Sciences Cash Flow from Operations Historical Data

The historical data trend for Cassava Sciences's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Operations

Get a 7-Day Free Trial

-2.51

-5.38

-30.20

-77.51

-82.03

Cassava Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Operations	Get a 7-Day Free Trial															-21.32	-13.26	-19.92	-26.53	-22.32

Cassava Sciences Cash Flow from Operations Calculation

Cassava Sciences's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Operations		(A: Dec. 2023 )
=	Net Income From Continuing Operations	+	Depreciation, Depletion and Amortization	+	Change In Working Capital	+	Deferred Tax
=	-97.217	+	1.53	+	9.076	+	0
+	Cash from Discontinued Operating Activities	+	Asset Impairment Charge	+	Stock Based Compensation	+	Cash Flow from Others
+	0	+	0	+	4.59	+	-0.0040000000000084
=	-82.03

Cassava Sciences's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:

	Cash Flow from Operations		(Q: Dec. 2023 )
=	Net Income From Continuing Operations	+	Depreciation, Depletion and Amortization	+	Change In Working Capital	+	Deferred Tax
=	-20.919	+	0.356	+	-3.882	+	0
+	Cash from Discontinued Operating Activities	+	Asset Impairment Charge	+	Stock Based Compensation	+	Cash Flow from Others
+	0	+	0	+	2.13	+	-0.00099999999999989
=	-22.32

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.03 Mil.

Cassava Sciences (NAS:SAVA) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Cassava Sciences's net income from continuing operations for the three months ended in Dec. 2023 was $-20.92 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Cassava Sciences's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $0.36 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Cassava Sciences's change in working capital for the three months ended in Dec. 2023 was $-3.88 Mil. It means Cassava Sciences's working capital declined by $3.88 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Cassava Sciences's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Cassava Sciences's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Cassava Sciences's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Cassava Sciences's stock based compensation for the three months ended in Dec. 2023 was $2.13 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Cassava Sciences's cash flow from others for the three months ended in Dec. 2023 was $-0.00 Mil.

Cassava Sciences Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences (Cassava Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » Cash Flow from Operations

Comparable Companies

Traded in Other Exchanges

SAVA:Mexico PX91:Germany PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Executives

Sanford Robertson	director	ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook	officer: SVP & General Counsel	6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec	officer: Chief Clinical Dev. Officer	7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen	officer: Chief Financial Officer	7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier	director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J	director
Robert Z Gussin	director
Scannon Patrick J Md Phd	director	C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann	director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p.	10 percent owner	405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174